Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.41 |
| ▸ | LOX | P28300 | 8/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 7/20 | 0.39 |
| ▸ | CA12 | O43570 | 6/20 | 0.39 |
| ▸ | CA9 | Q16790 | 6/20 | 0.39 |
| ▸ | SDCBP | O00560 | 1/20 | 0.38 |
| ▸ | SDC2 | P34741 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19274437 | 0.87 | LOX (0.44) | CA2LOXLOXL2CA1CA12 | |
| SCHEMBL19274445 | 0.87 | LOX (0.42) | CA2LOXLOXL2CA1CA12 | |
| SCHEMBL19259625 | 0.84 | CA2 (0.47) | CA2LOXLOXL2CA1CA12 | |
| SCHEMBL19274680 | 0.83 | LOX (0.57) | CA2LOXLOXL2CA1CA12 | |
| SCHEMBL19274287 | 0.82 | SDCBP (0.40) | CA2CA1CA12CA9SDCBP | |
| SCHEMBL19274286 | 0.81 | LOX (0.43) | CA2LOXLOXL2CA1CA12 | |
| SCHEMBL19274424 | 0.81 | LOX (0.50) | CA2LOXLOXL2CA1CA12 | |
| SCHEMBL19259978 | 0.80 | LOX (0.47) | CA2LOXLOXL2CA1CA12 | |
| SCHEMBL19274705 | 0.79 | LOX (0.48) | CA2LOXLOXL2CA1CA12 | |
| SCHEMBL21016309 | 0.79 | CA1 (0.41) | CA2LOXLOXL2CA1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2023-03-21 | — | — | US | disclosed |
| US-20220372028-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-11-24 | — | — | US | disclosed |
| WO-2017141049-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220372028-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | CA2 3985/4885LOX 4/4885LOXL2 3/4885 |
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | CA2 3985/4885LOX 4/4885LOXL2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.